REsistance to BEta-Lactam antibiotics due to extended-spectrum beta-lactamases in the Netherlands

REsistance to BEta-Lactam antibiotics due to extended-spectrum beta-lactamases in the Netherlands - The REBEL-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36316

Enrollment

2700

Registered

2010-03-25

Start date

2010-08-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dragerschap van ESBL-producerende bacteriën carriage with ESBL-producing bacteria

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Observational study part 1: consecutive patients attending general practices or belonging to the outpatients population/primary care population, all patients aged 18 years or older and mentally competent. Observational study part 2 (in combination with the GGD): also patients

Exclusion criteria

Exclusion criteria: Observational study part 1: age younger than 18 years and mentally incompetent; For approaching patients by postal mail (using the patient file of the GP), GPs will exclude patients who are terminally ill or otherwise not properly approachable. GPs will go through the database of the patient file and sort them out personally. Observational study part 2: mental incompetent patients.

Design outcomes

Primary

Measure	Time frame
According to the first part of the observational study we aim to include 2000 to 3000 patients. The main study parameter is the enrollment of 2000 to 3000 patients which filled in an informed consent, completed the questionnaire and returned a rectal swab or faecal sample. Also 550 participants attending the GGD will be asked to participate. According to the second part of the observational study we aim to include 50 patients carrying ESBL-producing strains. The main study parameter of this part is the enrollment of these 50 patients accompanied with the participation of the household members as many as possible.	—

Measure

Time frame

According to the first part of the observational study we aim to include 2000 to 3000 patients. The main study parameter is the enrollment of 2000 to 3000 patients which filled in an informed consent, completed the questionnaire and returned a rectal swab or faecal sample. Also 550 participants attending the GGD will be asked to participate. According to the second part of the observational study we aim to include 50 patients carrying ESBL-producing strains. The main study parameter of this part is the enrollment of these 50 patients accompanied with the participation of the household members as many as possible.

—

Secondary

Measure	Time frame
After follow-up of the first fifty patients and their household members we will compare these human strains with animal strains but an evident endpoint is not applicable.	—

Countries

Netherlands

Outcome results